Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.60%GBPCHF+0.51%GBPTRY+0.41%AUDCHF+0.41%USDCAD-0.40%NZDCHF+0.39%EURCAD-0.34%GBPHKD+0.32%GBPUSD+0.31%CADJPY+0.29%GBPMXN-0.28%CHFJPY-0.28%USDTRY+0.28%EURCHF+0.26%AUDSGD+0.25%NZDSGD+0.24%NZDUSD+0.23%USDNOK-0.22%EURGBP-0.21%AUDUSD+0.21%NZDCAD-0.21%GBPJPY+0.20%USDCHF+0.19%GBPSGD+0.19%AUDCAD-0.19%USDZAR-0.18%NZDMXN+0.17%USDSEK-0.17%USDPLN-0.17%EURSGD+0.16%USDILS+0.16%CHFSGD+0.15%SGDJPY-0.15%EURHKD+0.12%USDDKK-0.12%EURAUD-0.11%NZDJPY+0.11%GBPAUD+0.11%AUDJPY+0.11%CHFNOK-0.11%NOKJPY+0.11%EURNZD-0.10%EURNOK-0.10%USDJPY-0.10%EURCNH+0.09%AUDDKK+0.09%EURUSD+0.08%GBPCAD-0.08%GBPNZD+0.08%CHFSEK-0.06%PLNJPY+0.06%USDTHB+0.06%EURZAR-0.05%EURSEK-0.05%EURPLN-0.05%USDSGD+0.05%USDCOP-0.04%GBPZAR-0.03%USDMXN-0.03%USDCNH-0.03%EURCZK+0.01%EURJPY-0.01%AUDNZD+0.01%AUDNOK-0.01%USDHKD+0.01%EURDKK0.00%COTTON+0.97%HG1+0.72%XNGUSD+0.44%S1+0.37%W1-0.28%UKOIL-0.28%USOIL-0.22%XPTUSD-0.15%XAGUSD-0.06%GAGUSD-0.06%C1-0.05%GAUUSD-0.04%BTCUSD+2.39%ETHUSD+17.67%USDTUSD+0.01%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.80%ZECUSDT+8.47%DOGEUSD+14.12%XMRUSDT+5.42%LINKUSD+13.42%XLMUSD-0.06%BCHUSDT+5.33%UNIUSD+7.42%LTCUSD+9.66%SUIUSD+3.23%HBARUSDT+0.18%TONUSD+26.15%TAOUSDT+3.38%AAVEUSD+3.30%DOTUSDT-0.45%ICPUSDT+0.17%ONDOUSDT+0.19%WLDUSDT-0.60%ARBUSDT+6.37%JUPUSDT+0.62%ATOMUSDT+1.29%INJUSDT+13.43%STXUSDT+6.52%FETUSDT+2.08%TIAUSDT+8.81%PYTHUSDT+0.62%SEIUSDT+4.57%IMXUSDT+0.06%OPUSDT+19.70%GRTUSDT+3.86%IOTAUSDT+0.60%WIFUSDT+2.21%AXSUSDT-1.66%POLUSDT+2.60%FARTCOINUSDT+0.63%EOSUSDT+1.66%DYDXUSDT+3.87%GALAUSDT-1.87%ORDIUSDT-0.21%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.60%GBPCHF+0.51%GBPTRY+0.41%AUDCHF+0.41%USDCAD-0.40%NZDCHF+0.39%EURCAD-0.34%GBPHKD+0.32%GBPUSD+0.31%CADJPY+0.29%GBPMXN-0.28%CHFJPY-0.28%USDTRY+0.28%EURCHF+0.26%AUDSGD+0.25%NZDSGD+0.24%NZDUSD+0.23%USDNOK-0.22%EURGBP-0.21%AUDUSD+0.21%NZDCAD-0.21%GBPJPY+0.20%USDCHF+0.19%GBPSGD+0.19%AUDCAD-0.19%USDZAR-0.18%NZDMXN+0.17%USDSEK-0.17%USDPLN-0.17%EURSGD+0.16%USDILS+0.16%CHFSGD+0.15%SGDJPY-0.15%EURHKD+0.12%USDDKK-0.12%EURAUD-0.11%NZDJPY+0.11%GBPAUD+0.11%AUDJPY+0.11%CHFNOK-0.11%NOKJPY+0.11%EURNZD-0.10%EURNOK-0.10%USDJPY-0.10%EURCNH+0.09%AUDDKK+0.09%EURUSD+0.08%GBPCAD-0.08%GBPNZD+0.08%CHFSEK-0.06%PLNJPY+0.06%USDTHB+0.06%EURZAR-0.05%EURSEK-0.05%EURPLN-0.05%USDSGD+0.05%USDCOP-0.04%GBPZAR-0.03%USDMXN-0.03%USDCNH-0.03%EURCZK+0.01%EURJPY-0.01%AUDNZD+0.01%AUDNOK-0.01%USDHKD+0.01%EURDKK0.00%COTTON+0.97%HG1+0.72%XNGUSD+0.44%S1+0.37%W1-0.28%UKOIL-0.28%USOIL-0.22%XPTUSD-0.15%XAGUSD-0.06%GAGUSD-0.06%C1-0.05%GAUUSD-0.04%BTCUSD+2.39%ETHUSD+17.67%USDTUSD+0.01%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.80%ZECUSDT+8.47%DOGEUSD+14.12%XMRUSDT+5.42%LINKUSD+13.42%XLMUSD-0.06%BCHUSDT+5.33%UNIUSD+7.42%LTCUSD+9.66%SUIUSD+3.23%HBARUSDT+0.18%TONUSD+26.15%TAOUSDT+3.38%AAVEUSD+3.30%DOTUSDT-0.45%ICPUSDT+0.17%ONDOUSDT+0.19%WLDUSDT-0.60%ARBUSDT+6.37%JUPUSDT+0.62%ATOMUSDT+1.29%INJUSDT+13.43%STXUSDT+6.52%FETUSDT+2.08%TIAUSDT+8.81%PYTHUSDT+0.62%SEIUSDT+4.57%IMXUSDT+0.06%OPUSDT+19.70%GRTUSDT+3.86%IOTAUSDT+0.60%WIFUSDT+2.21%AXSUSDT-1.66%POLUSDT+2.60%FARTCOINUSDT+0.63%EOSUSDT+1.66%DYDXUSDT+3.87%GALAUSDT-1.87%ORDIUSDT-0.21%RONINUSDT-3.42%NOTUSDT+1.21%
PT

Protagonist Therapeutics, Inc. (PTGX)

NASDAQ • Healthcare

$138.49
-$6.38 (-4.4%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$146
Day Range$137.88 - $146
Avg. Volume (3M)851.3K
Market Cap$8.9B
P/E Ratio113.5
52 Week Range
$73.08$160.81
Next EarningsIn 22 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$213.4M100%
Gross Profitminus cost of goods$213.4M100%
Operating Incomeminus R&D and overhead$158.7M74%
Net Incomeminus taxes and the rest$162.8M76%

In plain terms: out of every $100 in revenue, Protagonist Therapeutics, Inc. keeps $76 as net profit.

Fundamentals & Financials

Revenue (TTM)
$281.9M
Net Income (TTM)
$82.9M
EPS (TTM)
$1.22
ROA (TTM)
9.36%
Current Ratio
21.71

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-30.2%Q1 2026-$0.69
+107.7%Q2 2026$0.05
+2.7%Q3 2026$2.29
Next

Nov 5

in 22 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +2.7%

Operating cash flow came in at about $219.1 million for Protagonist Therapeutics’ second fiscal quarter of 2026, which the company reported on August 5, 2026, reflecting cash generation alongside ongoing work across its peptide-based pipeline in blood, inflammatory, and immune-mediated disorders, including programs such as rusfertide (PTG-300) and inflammatory bowel disease candidates PN-943 and PN-235. Consensus for the next period calls for EPS of $2.43 on revenue of $240.1 million.

Next report — what to expect

Protagonist Therapeutics, Inc. (PTGX) reports next on November 5, 2026. With consensus EPS and revenue not available, traders may focus on management’s updates around pipeline progress and any commentary tied to near-term milestones. PTGX has beaten EPS in 5 of its 8 most recent quarters, which helps frame recent reporting variability.

View full earnings history

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on discovering and advancing peptide-based therapies for blood, inflammatory, and immune-mediated disorders. The company develops clinical candidates across hematological and broader blood conditions as well as inflammatory disease, and generated $46.0 million of revenue in FY2025.

Name
Protagonist Therapeutics, Inc.
CEO
Dinesh V. Patel
Website
www.protagonist-inc.com
Industry
Healthcare
Year Founded
2006
Employees
141

Today's Snapshot

AI-generated

PTGX closed 4.4% lower at 138.49, in line with a weaker sector.

Trading Volume

Above 10d avg 872.3K

1M

vs S&P 500 Today

Strong Underperformance

-4.39%

Updated: October 13, 2026 at 20:09 UTC

PTGX Headlines

Tom Steyer backs select biotech names

May 2, 2026

3 min read

Fresh Valuation Checks Across Key Stocks

April 4, 2026

6 min read
View All News

Technical Indicators

2 Buy3 Neutral3 Sell
PTGX is trading around 138.49 and sits below its short-term averages while remaining above the 100- and 200-day levels, producing a mixed price structure. Trend strength is muted with ADX near 17, and momentum indicators are tepid—RSI in the mid-40s and MACD slightly negative—while a short-term momentum reading is modestly bearish. Volatility is moderate given an ATR near 5.7 and Bollinger bands roughly spanning the mid-130s to mid-140s, and on-balance volume points to accumulation. Classic and Fibonacci pivots cluster near 146.92, marking nearby resistance. Technical takeaway: Neutral.
All signals
  • EMA (5 indicators)$116.45 - $141.93
    Sell
  • RSI (14)43.28
    Neutral
  • Stochastic %K (14, 3, 3)51.54
    Neutral
  • MACD Level (12, 26)-0.96
    Neutral

Peers & Related Assets

SYRESpyre Therapeutics, Inc.
$80.45-6.3%
IMVTImmunovant, Inc.
$28.71-2.6%
IRONDisc Medicine, Inc.
$56.6-6.4%
ANABAnaptysBio, Inc.
$45.59-1.0%
ODTXOdyssey Therapeutics, Inc.
ACRSAclaris Therapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.